Page 1,520«..1020..1,5191,5201,5211,522..1,5301,540..»

Miss Michigan raising awareness about diabetes – Fox 2 Detroit

Posted: April 28, 2017 at 1:49 am

(WJBK) - In just over two weeks, Miss Michigan Krista Ferguson will be traveling to Las Vegas to compete for the title of Miss USA.

While she has the spotlight, she's using the attention to raise awareness about diabetes. She was diagnosed with Type 1 diabetes two years ago.

Type 1 diabetes, also known as juvenile-onset, is where the body's immune system destroys the cells that release insulin, versus Type 2 diabetes in which your body can't use insulin the right way. Type 2 typically develops in adulthood.

Krista is giving herself about four shots every day, as well as pricking her finger multiple times to check her blood sugar. She also keeps a patch on her leg that continuously checks her blood sugar, and she gets alerts on her phone if her levels are changing too quickly.

Krista wants others to know that your illness doesn't define you.

"It may be a part of you but it will never stop you from conquering your dreams and achieveing your goals," she says.

You can watch Krista compete in the Miss USA competition right here on FOX 2 on May 14, 2017 at 7 p.m.

Read this article:
Miss Michigan raising awareness about diabetes - Fox 2 Detroit

Posted in Diabetes | Comments Off on Miss Michigan raising awareness about diabetes – Fox 2 Detroit

Future of Diabetes Care Paradigms, Forecast to 2022 – Yahoo Finance – Yahoo Finance

Posted: April 28, 2017 at 1:49 am

LONDON, April 27, 2017 /PRNewswire/ -- Diabetes management is on the verge of being disrupted by innovative technologies such as artificial pancreas, non-invasive glucose monitoring sensors, wearables, apps, and inhalable insulin. This research study captures all the innovative developments across the segments of wellness, diagnosis, monitoring, and therapy of the diabetes care continuum, covering the global market.

Download the full report: https://www.reportbuyer.com/product/4842301/

Diabetes remains one of the top causes of mortality, and health expenditure on the disorder and its complications is set to rise 19% annually until 2040, to reach $802 billion. Beyond the traditional focus and high-interest areas of monitoring and therapy, rising diabetes prevalence and costs are resulting in the focus gradually shifting to preventing diabetes, and on the overall wellbeing of diabetics and pre-diabetics, resulting in the highest double-digit growth of the wellness segment. Diagnosis, however, remains a neglected aspect of diabetes and novel approaches may be necessary to improve screening and diagnosing patients earlier to save on long-term costs. Monitoring developments that help improve the quality of life of diabetics include blood glucose monitoring tech advances (traditional glucometers and also semi-invasive, implants, and non-invasive continuous glucose monitoring systems), data analytics support, care delivery support, and overall diabetes management support in the form of apps, telehealth, and insulin dosing calculation support. Therapy, the largest segment, is also seeing several improvements in terms of better drugs, combination drugs, better insulin forms, and better delivery mechanisms. Of course, the main development in this segment is that of artificial pancreasthere is one commercially available system and several being developed with varying approaches and features. The other notable "permanent cure" approach is cell therapy involving regenerative medicine techniques with variations in the approaches for transplantation.

The study provides an exhaustive coverage of the overall diabetes ecosystem, with strong focus on startups, apart from the existing stakeholders. It also analyzes the role that technology giants such as Alphabet (ne Google) and IBM are playing in the diabetes space. An overview of several innovative diabetes care delivery models from across the world is also included. The study would be valuable for diabetes stakeholders to chart out their strategies for future collaborations and partnerships, while keeping a watchful eye on the competition.

Key questions this study will answer: How is the diabetes burden evolving across the globe? How are market forces and trends shaping the diabetes market and the segments of wellness, diagnosis, monitoring, and therapy? What gaps in diabetic care need to be filled to address the unmet needs of diabetics? What are the technological developments in the industry that attempt to address such unmet needs? How have some care models perfected diabetes management, catering to local needs? What are some future perspectives for the industry? Download the full report: https://www.reportbuyer.com/product/4842301/

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: http://www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/future-of-diabetes-care-paradigms-forecast-to-2022-300447395.html

See the rest here:
Future of Diabetes Care Paradigms, Forecast to 2022 - Yahoo Finance - Yahoo Finance

Posted in Diabetes | Comments Off on Future of Diabetes Care Paradigms, Forecast to 2022 – Yahoo Finance – Yahoo Finance

Andrews Institute Looks Ahead – Inweekly

Posted: April 27, 2017 at 10:47 am

By Duwayne Escobedo

At a recent press conference in honor of his facilitys 10th anniversary, Dr. James Andrews told the story about the moment he knew the Andrews Sports Medicine and Orthopaedic Center partnership with Baptist Health Care would happen.

Baptist Health Care brought its top executives to approach him for a second time in December 2003 about teaming up to start a sports medicine medical center in Gulf Breeze. He had just finished surgery at his Birmingham, Ala., center and welcomed the group into a small adjacent office.

Baptist Health Care CEO, Al Stubblefield envisioned building the Andrews Institute next to Gulf Breeze Hospital and providing its world-class medical care to the community. He was told about Andrews and his celebrity as a top sports orthopaedic surgeon. Stubblefield said, I dont know what an athletic trainer is, but I want some.

However, other Baptist officials werent convinced, especially Baptist Chief Financial Officer Joe Felkner.

During a tour of the Andrews sports medical center in Alabama, Felkner spotted USA Olympic gymnast Blaine Wilson doing rehab on an injured shoulder. Wilson grew up in Columbus, Ohio, and starred on Ohio States gymnastics team. Felkner was a big Buckeyes fanatic.

It was a damn miracle, Andrews said. He always played the bad guy. But right away he said, We got to do this. Thats really how we got the financing done.

A decade later, Andrews Institute in Gulf Breeze has made a huge impact on the Florida Gulf Coast region. It is estimated to have an economic impact on the region of tens of millions of dollars. The cutting-edge, world-renowned sports medicine center celebrated its achievements at its 10th anniversary Wednesday in the Andrews Athletic Performance and Research Pavilion.

Its been a magnificent journey for all of us, said Andrews, who thanked local government officials, Baptist executives, his team of more than 50 physicians, and wife, Jenelle. He also singled out longtime friend Jerry Pate and Ed Gray for securing funding from then-Governor Jeb Bush that helped make the Florida center a reality.

The funding allowed Andrews Institute to open the doors to its 126,535-square-foot sports medicine center in April 2007 that feels more like an upscale, luxurious hotel than a hospital. It features an ambulatory surgery center, an athletic performance center, and a research and education center.

Over its first 10 years, Andrews Institute performed more than 6,000 surgeries, provided athletic trainers freely to 25 public high schools from Escambia to Walton County and three area colleges, trained 57 fellows under its top-notch physicians, and worked to develop the next generation of sports medicine tools at its Regenerative Medicine Center.

Not only did it look back at its achievements at the press conference, the sports medicine center looked forward to what the next decade might hold for the institute.

One promising development is the use of stem cells to help speed up the healing process, regenerate tissue, cartilage and organs and lead to other cures for diseases, such as diabetes, arthritis and osteoporosis.

Dr. Adam Anz, an Andrews orthopaedic surgeon and sports medicine specialist, is overseeing a stem cell study that starts in May. He said stem cells are five to seven years away from earning FDA approval for medical uses and becoming widely used to treat patients. Stem cells are considered the biggest advance in sports medicine since arthroscopy surgery, which allows physicians to make a small incision on a patient and use a tiny camera to surgically repair knees, rotator cuffs, and other common debilitating sports injuries.

Anz talked excitedly about regenerative medicine. Today, bone marrow aspiration typically produces about 17,000 stem cells, while140 million stem cells come from a variety of regenerative sources, such as embryos, gestational and adult tissues, and reprogrammed differentiated cells.

The FDA is a lot like the IRS, Anz explained. We need to refine and prove to them that they work. There are future products, and they need development.

Andrews agreed. He said: Were still at the tip of the iceberg. Its coming though. Regenerative medicine will revolutionize not only what we do in sports medicine but all surgeries.

Another impact that Andrews Institute has had on the region is its sports medicine outreach to youth. The public service ensures sports medicine coverage freely to all of the public high schools in Escambia, Santa Rosa, Okaloosa and Walton counties and has plans to expand to other Northwest Florida counties, including Bay County. It includes performing baseline concussion tests for more than 4,500 youth athletes since 2015.

Only 37 percent of public high schools have a full-time athletic trainer, reports the NATA Research and Education Foundation.

Andrews led a charge in 2015 in the Florida Legislature to require all Florida High Schools to have at least one athletic trainer. But the legislation never passed.

Its getting to where it will be a medical legal issue, Andrews predicted. Right now my passion is youth sports.

Dr. Roger Ostrander was one of the first orthopaedic surgeons to relocate to Gulf Breeze in July 2004.

When I got here in 2004, I didnt understand the scope and magnitude of this project. Its unique in the country, Ostrander said. I feel very fortunate to be part of Andrews Institute from the beginning.

Andrews Institute By the Numbers 2007-2017 650,000+ Visits to Andrews Institute Rehabilitation location since 2008 61% Increase in patient volume since 2008 228,000+ X-ray and MRI exams completed since 2007 50,864 Patients/Cases seen at the Andrews Institute Ambulatory Surgery Center 303% Increase in patient volume since 2007 20,000 Free pre-participation exams performed 68,500 Injury assessments performed 1,800 Injury assessments performed at Saturday morning Student-Athlete Injury Clinic 4,500 Concussion baseline tests performed since 2015 400 Community events with Andrews Institute sports medicine coverage 84 Clinical research studies conducted over the last 10 years 19 Open clinical research studies from July 2015 to June 2016 112 Wounded or injured Special Operations military members treated from July 2015 to June 2016

Read the original here:
Andrews Institute Looks Ahead - Inweekly

Posted in Alabama Stem Cells | Comments Off on Andrews Institute Looks Ahead – Inweekly

UMN research team fixes broken hearts with 3D-printed tissue patch – Minnesota Daily

Posted: April 27, 2017 at 10:47 am

A research team at the University of Minnesota found a way to heal broken hearts.

Researchers used a 3D printer to create protein patches that mimic heart tissue to treat post-heart attack scars. The research is in collaboration with the University of Wisconsin-Madison and the University of Alabama-Birmingham.

Brenda Ogle, a University biomedical engineering professor and lead researcher for the project, said she and her team have investigated proteins that surround cells in the body for 15 years. The team has been studying how the proteins also called the extracellular matrix influence stem cell behavior.

For many years, weve been trying to develop optimum formulation that can support stem cells in new cardiac [cell] types, Ogle said, adding that theyve focused on cardiac cell types to figure out a way to strengthen them after the muscle cells are damaged and die during a heart attack. Its one of the cell types in the body that cant be recovered.

The team successfully treated mice with the patches and is now planning to test the method on larger animals.

Molly Kupfer, a doctoral student who is part of Ogles team, said a heart attack occurs when there is a blockage in a primary blood vessel that delivers oxygen and nutrients to the heart.

When that happens, you have cell death in the area of the heart that doesnt receive the appropriate oxygen and nutrients, Kupfer said. Those cells that die arent able to recover."

Typically, after a heart attack, the blood clot in the heart is removed at a hospital, and if the heart has not been damaged too badly, doctors monitor the heart long-term, prescribe medicine and regularly check for signs of heart failure, Ogle said.

What you get instead after a heart attack is scar tissue forming, and that scar tissue ultimately fails, Ogle said.

Associate Professor Brenda Ogle places a 3D printed biopatch on a mouse heart in Nils Hasselmo Hall on Tuesday, April 25, 2017. Her research team induces heart attacks in mice, which causes a dead area of cardiac cells. The patch is placed in this dead zone and mimics the cells of the native heart that aren't able to be replenished on their own.

Kupfer said she worked with Paul Campagnola and his lab at the University of Wisconsin to print the patches; the cells were prepared at the University of Minnesota.

Campagnola, a biomedical engineering professor, said he initially developed the underlying printing technology in 2000.

"The idea of the patch is it could actually behave like native cardiac tissue and assist the function of the heart, Kupfer said, adding that the method used to print the patches results in extremely high resolution structures.

Ogle said before applying the patch to the animal hearts theyre currently testing on, they take a scan of the scarred tissue and create a digital template for the 3D-printer to follow and print the proteins in the same pattern.

Campagnola said the patch provides a stable space for cells to grow and be implanted in damaged areas.

Cardiac cells are also added to the patch when it covers a damaged area. Ogle said it not only provides a support structure, but transplants healthy cells that will eventually become integrated into the heart, stabling it structurally and functionally.

A huge aha moment was when [the cardiac cells] started to beat on this patch synchronously and spontaneously, she said. When that happened, we realized that this could be a viable therapy for the heart, a way to replace those lost muscle cells.

Through the research group at the University of Alabama, Ogle said a study was conducted where the patch was tested on dead or dying tissue in mice hearts and the group saw improvement in the mice after four weeks.

The project was funded through a series of grants from the National Institutes of Health, the National Science Foundation with support from the University, she said.

The group has since received larger funds from the NIH to run a study using the patch on larger animals within the next year.

Ogle said it would take about 10 years until the patch can be used on human patients in a clinical setting.

Follow this link:
UMN research team fixes broken hearts with 3D-printed tissue patch - Minnesota Daily

Posted in Alabama Stem Cells | Comments Off on UMN research team fixes broken hearts with 3D-printed tissue patch – Minnesota Daily

Bengals set to hold onto McCarron for at least 1 more year | Sports … – Newsexaminer

Posted: April 27, 2017 at 10:47 am

CINCINNATI Bengals backup quarterback AJ McCarron is looking at another year of barely getting on the field, and maybe longer.

With the draft a few days away, Cincinnati has given no indication its willing to trade him to a team that would give him a bigger role. Its a challenging situation for McCarron, who proved he could lead a team into the playoffs in 2015 if given the opportunity.

As a competitor, you always want your chance to play, McCarron said Monday. But it will happen. I just have to wait my time. I believe that, and I trust in my ability to keep showcasing what I can do and then get my opportunity.

The two-time national champion at Alabama got his chance when Andy Dalton broke the thumb on his passing hand late in the 2015 season. McCarron, a fifth-round pick, started the last three games and won two of them. His late touchdown pass to A.J. Green had Cincinnati ahead in the closing minutes of a playoff game against Pittsburgh before a pair of defensive penalties helped the Steelers move in range for the winning field goal.

Last year, he was relegated to a backup role again, getting into only one game without throwing a pass.

Although theres great demand in the NFL for starting quarterbacks, the Bengals havent shown an inclination to trade him. Theyre content having him as the backup in case Dalton gets hurt again.

Its great to be wanted, it really is, McCarron said.

Even so, its difficult to go back to being the backup after leading a team to the playoffs. Dalton has been extremely durable during his six-year career the broken thumb was his only significant injury so the odds are against McCarron getting much chance to play until his contract ends.

Hes in a situation similar to Jimmy Garoppolo in New England, which hasnt shown an inclination to trade Tom Bradys backup.

McCarrons original deal runs through this season, but theres a catch. He showed up for training camp with a sore shoulder as a rookie in 2014 and was unavailable for most of the season, which could affect his status. Instead of being an unrestricted free agent, the Bengals think he should be a restricted free agent after the 2017 season because he missed most of his rookie season.

As a restricted free agent, McCarron could wind up spending the 2018 season in Cincinnati as well.

Were still going through all that, McCarron said. And its probably going to go into next year. Its just something theyre going to fight on their side and something Im going to fight on my side to prove why I shouldnt have to have another year.

McCarrons eagerness to move into a starters role is tempered by his appreciation for how the Bengals drafted him. They stuck with him after he missed most of his rookie season because of the sore shoulder, which improved after he got stem cells injected. In a year or two, hell get his chance.

There were some quarterbacks that got some pretty nice pay days this offseason, McCarron said. Hopefully in my future, one of those days is coming up.

See original here:
Bengals set to hold onto McCarron for at least 1 more year | Sports ... - Newsexaminer

Posted in Alabama Stem Cells | Comments Off on Bengals set to hold onto McCarron for at least 1 more year | Sports … – Newsexaminer

Improving Joint Health with Putative Therapeutics at Matis, Iceland’s Food & Biotechnology Research Institute – SelectScience

Posted: April 27, 2017 at 10:47 am

Use of cell imaging technology enables cutting-edge research into the assessment of bioactive compounds in cell lines

Matis is a leading food and biotechnology research institute in Iceland. Matis vision is to increase the value of food processing and food production, and to ensure the safety and quality of food and food products. SelectScience spoke to Dr. Eva Kuttner, to learn more about the technology the company is using in its research.

SS: Could you briefly introduce yourself and your place of work?

EK: My name is Dr. Eva Kuttner, Im a Project Leader in the Analysis and Structure division at Matis (mat=food + is=Iceland). Matis is a government owned, non-profit, independent research company in Iceland. The main focus of Matis is research and development, aligned to the food and biotechnology industries, as well as providing Iceland's leading food analytical testing service for public and private authorities.

I personally am German, and I hold a Diploma (equal to an MSc) in Botany, from the Universitt Braunschweig in Germany. I received my PhD in Integrative Biology (2007-2012) from the University of Guelph (Ontario, Canada).

SS: Could you describe your job role and work at Matis?

EK: My job title is Regional Manager, which means I am responsible for the 2 locations of Matis in the North of Iceland, Saurkrkur and Akureyri. My main work is that of a project leader (bioactives) in the Analysis and Structure Division and I am specialized in screening for bioactive secondary metabolites using in vitro chemical and cell-based assays.

Our laboratory focus is on identifying and describing compounds regarding antioxidant activity for healthcare (anti-diabetes, anti-inflammatory) and skin care. We now have a fully equipped cell laboratory (currently working with two cell lines), and we routinely run chemical and cell-based assays to identify and describe the bioactivity properties of extracted and fractionated compounds.

Testing putative therapeutics

SS: Please tell us about your marine compounds project that you are working on, and the main challenges involved?

EK: We are currently looking into how marine compounds influence the mineralization in a murine chondrocyte cell line (ATDC5). The aim of the project is to test putative therapeutics, to improve joint health. Specifically, we are interested in seeing how they affect differentiation of these cells.

SS: Which methods do you use to investigate this project and how does the BioTek Cytation 5 play a part in this?

EK: We are exposing the cells to different concentrations of fractionated marine compounds in a 96-well microplate format. After 24 days of incubation we stain the cells both with calcein and Alizarin Red to quantify calcium deposition. This is when the Cytation 5 from BioTek comes in: we have a workflow set up that images (magnification 4x) each well in phase contrast and fluorescence (we are using a GFP filter cube for this assay), and also carries out a read of the fluorescence signal. We then perform the Alizarin Red staining, take more pictures and extract the bound color after several washing steps. A further reading step quantifies the Alizarin Red using an absorbance read.

The figure below shows an example read of the calcein stain: first picture, phase contrast, second picture, fluorescence channel (GFP filter cube) and the third picture, overlay of both:

Image courtesy of Dr. Eva Kuttner

SS: What are your main research findings so far?

EK: We have identified several possible inhibitors of mineralization, but we are still in the process of improving the assay protocol to make the quantification of the mineralization more reproducible. The Alizarin Red stain has proven to represent more accurate calcium deposition into the cells, when testing the assay protocol using standard inhibitors like levamisole, so we are using the calcein stain to visualize mineralization, and Alizarin Red to quantify.

SS: What is the future of your research?

EK: We are looking into setting up assays investigating blood pressure. Our project partner developed a product line based on fish protein hydrolysate using trimmings from cod (Gadus morhua). The proteins are extracted and broken down to smaller peptides that have been shown to inhibit a key enzyme involved in increasing blood pressure (ACE). For this research we will develop and perform cell-based assays.

Go here to read the rest:
Improving Joint Health with Putative Therapeutics at Matis, Iceland's Food & Biotechnology Research Institute - SelectScience

Posted in Biotechnology | Comments Off on Improving Joint Health with Putative Therapeutics at Matis, Iceland’s Food & Biotechnology Research Institute – SelectScience

250598 Shares in Puma Biotechnology Inc (PBYI) Acquired by Norges Bank – The Cerbat Gem

Posted: April 27, 2017 at 10:46 am

250598 Shares in Puma Biotechnology Inc (PBYI) Acquired by Norges Bank
The Cerbat Gem
Puma Biotechnology logo Norges Bank acquired a new position in Puma Biotechnology Inc (NYSE:PBYI) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 250,598 shares of the biopharmaceutical ...
-$2.08 EPS Expected for Puma Biotechnology Inc (PBYI) This QuarterSports Perspectives
Analyst Observation On 2 Stocks: Delta Technology (DELT), Puma Biotechnology (PBYI)Post Analyst

all 4 news articles »

Read more here:
250598 Shares in Puma Biotechnology Inc (PBYI) Acquired by Norges Bank - The Cerbat Gem

Posted in Biotechnology | Comments Off on 250598 Shares in Puma Biotechnology Inc (PBYI) Acquired by Norges Bank – The Cerbat Gem

3D Systems and United Therapeutics partner to 3D print organ scaffolds for human transplants – TCT Magazine

Posted: April 27, 2017 at 10:46 am

3D Systems has announced a bioprinting agreement with United Therapeutics which will see the two companies develop solid-organ scaffolds for human transplants with 3D printing.

Combining their respective expertise in 3D printing and regenerative medicine and organ manufacturing, the collaboration will remain for a number of years.

The agreement will pit 3D Systems personnel alongside professionals from a United Therapeutics subsidiary, Lung Biotechnology PBC. Since the collaboration will primarily focus on the development of 3D printing systems for solid-organ lung scaffolds, Lung Biotechnology PBC is seen as best placed to work with 3D Systems.

The printing system will target collagen, and other building block proteins, as scaffold raw materials. Lung Biotechnology PBC will cellularize the scaffolds with patient-specific biological material, including re-differentiated stem cells.

Our partnership with 3D Systems is a major step forward in creating an unlimited supply of tolerable transplanted organs, said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. By cellularizing scaffolds created with 3D Systems printers with a patients own cells, there will no longer be a need for immunosuppression and a vastly greater number of patients can extend their enjoyment of life through organ transplantation.

3D Systems is a company with a wealth of experience in the medical sector. Its precision healthcare capabilities include simulation, virtual surgical planning, and the printing of medical and dental devices. Two of 3D Systems leading executives are not only confident in their companys own knowledge of the medical 3D printing sector, but also of United Therapeutics own expertise. Though conceding the challenge is not straight forward, the pair foresee new solutions being born from the partnership.

As a global leader in healthcare solutions, we are part of many developments and applications for 3D printing coming together including bioprinting, said Vyomesh Joshi, Chief Executive Officer, 3D Systems. We believe bioprinting is a powerful opportunity and we are uniquely positioned with the broadest portfolio of technologies to partner with companies of the calibre of United Therapeutics to provide healthcare solutions of the future.

Chuck Hull, Executive Vice President, Chief Technology Officer, 3D Systems, added: Combining the resources of United Therapeutics and 3D Systems transforms our capability to tackle this difficult challenge. This project will be based out of our new bioprinting lab in San Diego, CA, and will rely on expertise across many technical disciplines within 3D Systems as well as the domain knowledge of our technical partners at Lung Biotechnology PBC.

Meanwhile, the collaboration and joint development will add another technology alternative to United Therapeutics pursuit of an unlimited supply of organs for human transplantation.

Dr Rothblatt concludes: Our Lung Biotechnology public benefit corporation is taking personal regenerative medicine to its highest level yet with this practical, economic solution to a major health care program. Indeed, we expect one personalised organ transplant will avoid years of health care spending on palliative medical therapies.

Follow this link:
3D Systems and United Therapeutics partner to 3D print organ scaffolds for human transplants - TCT Magazine

Posted in Biotechnology | Comments Off on 3D Systems and United Therapeutics partner to 3D print organ scaffolds for human transplants – TCT Magazine

Lonza US cell therapy plant slapped with FDA warning letter – FiercePharma

Posted: April 27, 2017 at 10:44 am

Swiss CDMO leader Lonza has had its cell therapy facility in the U.S. slapped with a warning letter after halting some production there two months ago because of sterility problems with a product it was producing for a client.

The company acknowledged the FDA action in its first-quarter earnings report Tuesday, saying that the warning letter was issued Monday for its facility in Walkersville, Maryland. The FDA had concerns about issues including validation and aseptic process simulations, the drugmaker said.

Lonza takes this issue seriously, and has already started to address all issues raised by the FDA, the company said.

Lonza first learned about the issue in December after product end-user notified the FDA of the issue, Lonza spokeswoman Constance Ward said in an email Tuesday. Lonza opened an investigation after confirming the sterility issue. She said the plant halted production of the product in the affected manufacturing area in early February, while also quarantining the inventory it had on hand.

"After inspecting both the customer of the product and the Walkerville operations, the FDA issued Lonza a warning letter that identified issues involving validation, aseptic process simulations, corrective and preventive actions, and environmental monitoring, Ward explained.

She said the company expects to have the problems resolved and FFM media manufacturing back online by mid-2017. The company had already begun a $7.6 million manufacturing upgrade at the facility, which Ward said is slated to be finished in 2018.

While the drugmaker said it expects the latest FDA action to have minimal impact on revenues of its Pharma & Biotech segment, it reported sales in the segment were softer in the first quarter because of the action. Without providing specific numbers, the contract manufacturer Tuesday reported that growth in that segment was driven by demand in mammalian manufacturing, as well as in clinical development and licensing.

This is not the first time that Lonza has faced FDA concerns about its biologics operations in the U.S. An API plant it had in Hopkinton, Massachusetts, was cited in 2011 over a plethora of problems, creating supply problems for a drug it manufactured there at the time for French drugmaker Ipsen. After struggling to get issues resolved, Lonza simply closed the plant and concentrated its biologics work at its extensive site in Visp, Switzerland.

Lonza is preparing to expand its Visp biologics capability further. It will break ground in the second half of the year on a new large-scale biologics production facility that it is building in partnership with Frances Sanofi. The companies announced in February that they would share the cost, and capacity, of a 270 million ($286.3 million) plant at Lonzas site in Visp.

Read the rest here:
Lonza US cell therapy plant slapped with FDA warning letter - FiercePharma

Posted in Cell Therapy | Comments Off on Lonza US cell therapy plant slapped with FDA warning letter – FiercePharma

HemaCare Will Attend International Society of Cell Therapy in … – Business Wire (press release)

Posted: April 27, 2017 at 10:44 am

LOS ANGELES--(BUSINESS WIRE)--HemaCare Corporation (OTCBB: HEMA), a leader in cell and tissue collection, processing and cell therapy solutions, will be exhibiting at the annual meeting of the International Society of Cell Therapy (ISCT) in London, UK, May 3-6, 2017. This year marks the 25th anniversary of the ISCT, a global society that unites clinicians, researchers, regulators, technologists and industry partners with a shared vision to translate cellular therapy into clinical practice. HemaCare will meet with its customers and European distributors at the conference and showcase its growing portfolio for cell therapy developers around the world.

Attending this meeting enables us to capture the latest developments in cell therapy and better serve our customer needs, said Pete van der Wal, Chief Executive Officer for HemaCare.The field of cell therapy is rapidly evolving. Our products and services are embedded in some of the most critical phases of translational research, enabling scientists to work with high quality human cells from our well-characterized donor pool.

The conference is being held at ExCel London Conference Center. Look for us there, or view our products and services at http://www.hemacare.com.

About HemaCare

HemaCare specializes in the customization of human-derived biological products and services for customers research and cell therapy protocols. HemaCares network of FDA-registered, GMP/GTP-compliant collection centers ensures donor material is available for fresh shipment to customers, as well as for internal use within HemaCares isolation laboratory. In this laboratory, human biological material such as peripheral blood, bone marrow, and cord blood from donor and patient subjects is isolated into various primary cell types for distribution to customers in fresh and frozen formats. HemaCare's extensive registry of well-characterized repeat donors provides consistent primary human cells and biological products for advanced biomedical research and cellular therapy process development.

For 39 years, HemaCare has provided human-derived primary blood cells and tissues for biomedical research, supported cell therapy clinical trials and commercialization with apheresis collections, and provided a wide range of consulting services. HemaCare directly supports benchtop immunology and oncology research, compound screening for drug discovery, and assay development and qualification, as well as enables customers to advance both autologous and allogeneic cellular therapies. For more information, please visit http://www.hemacare.com.

View post:
HemaCare Will Attend International Society of Cell Therapy in ... - Business Wire (press release)

Posted in Cell Therapy | Comments Off on HemaCare Will Attend International Society of Cell Therapy in … – Business Wire (press release)

Page 1,520«..1020..1,5191,5201,5211,522..1,5301,540..»